Request Trial
30 October 2014Asia

Intas granted injunction over anti-epilepsy drug trademark

Indian pharmaceutical company Intas Pharmaceuticals has been granted an injunction preventing a rival from marketing an anti-epilepsy drug it said infringed one of its trademarks.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Chinese biotech strikes billion dollar deal in nextgen cancer race
20 January 2026   Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.
Asia
Novo Nordisk secures China win ahead of key patent expiration
6 January 2026   Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.
Asia
Novo Nordisk ramps up semaglutide defence as generics lurk
9 December 2025   The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.


Editor's picks

Final call: Who are the world’s best in-house counsel?
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

Editor's picks

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025

More features

AI is transforming top 100 innovators, shows index
Novartis win blocks generics relitigating $7.8bn heart drug patent
Leading the arena: WIPR identifies the top US trade secrets specialists of 2025
Cadwalader global head among trio moving to Orrick
Skinny labels, big stakes: SCOTUS lines up the case of the year
Chinese biotech strikes billion dollar deal in nextgen cancer race
$5.4bn medtech leader fails to bury a rival's patent
Senior four-partner team leaves A&O Shearman